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The many faces of hematopoietic stem cell heterogeneity
Mihaela Crisan1 and Elaine Dzierzak2,*
ABSTRACT
Not all hematopoietic stem cells (HSCs) are alike. They differ in their
physical characteristics such as cell cycle status and cell surface
marker phenotype, they respond to different extrinsic signals, and
they have different lineage outputs following transplantation. The
growing body of evidence that supports heterogeneity within HSCs,
which constitute the most robust cell fraction at the foundation of the
adult hematopoietic system, is currently of great interest and raises
questions as to why HSC subtypes exist, how they are generated and
whether HSC heterogeneity affects leukemogenesis or treatment
options. This Review provides a developmental overview of HSC
subtypes during embryonic, fetal and adult stages of hematopoiesis
and discusses the possible origins and consequences of HSC
heterogeneity.
KEY WORDS: Hematopoiesis, HSC, Hematopoietic stem cells,
Heterogeneity, Hematopoietic niche
Introduction
Hematopoietic stem cells (HSCs) give rise to all cells in the blood
lineage through the process of hematopoiesis. In order to do this,
HSCs undergo self-renewal, retaining their multipotentiality and
thus their function throughout life. While it is convenient to think
of HSCs as a single, homogenous population, evidence from
recent years does not support this view. The concept that HSCs
can be sorted to homogeneity and that each HSC behaves
identically in reconstitution assays is under challenge. Clonal
HSC transplantations and refined cell sorting have identified HSC
subtypes with different functional properties, including differences
in repopulation kinetics (Benz et al., 2012; Dykstra et al., 2007;
Muller-Sieburg et al., 2012; Sieburg et al., 2006; Verovskaya et al.,
2013), cell cycle status (Wilson et al., 2008), self-renewal abilities
(Ema et al., 2014, 2005) and multilineage differentiation output
(Benz et al., 2012; Dykstra et al., 2007; Muller-Sieburg et al., 2012;
Sieburg et al., 2006; Verovskaya et al., 2013). Although the
evidence for HSC heterogeneity is strong, its source has yet to be
identified (see Fig. 1). Are HSC subtypes programmed intrinsically
during development? Or, do all HSCs begin life identically, with
heterogeneity determined by extrinsic factors encountered during
the migration and colonisation of HSCs in different developmental
tissues and their respective niches? These important issues, as well
as the physiological relevance of HSC heterogeneity, are beginning
to be addressed. In this Review, we summarise the current
knowledge regarding HSC heterogeneity in the mouse, as well as
recent efforts to tease apart different HSC subtypes and how they
might arise. Different HSC subtypes may be defined using refined
cell sorting techniques, based on either HSC cell surface markers,
endogenous reporters or differing responsiveness to signalling
pathways. We discuss these different phenotypic classifications of
HSC subtypes and consider the developmental aspects of HSC
emergence that might give rise to such heterogeneity.
HSC heterogeneity in adult bone marrow
The Muller-Sieberg group was among the first to define HSC
heterogeneity by observing the repopulation kinetics of single HSCs
following transplantation into irradiated or cKit receptor tyrosine
mutant (W/W) recipient mice (Sieburg et al., 2006). Statistical
analyses showed 16 types of kinetic repopulation patterns measured
over 8 months in recipients that received a clonal stem cell
transplantation from whole bone marrow. Clonal transplantation
of sorted Lin− Rho− side population (SP; see below) HSCs showed
selective enrichment of only some kinetic subsets of all of the HSC
types found in bone marrow. Moreover, daughter HSCs from
primary hosts, when transplanted into secondary hosts, followed the
same repopulation kinetics as the original transplanted HSC
(Muller-Sieburg et al., 2002). This result predicted that distinct
stable HSC subtypes exist and that HSC heterogeneity can be stably
propagated.
Heterogeneity in the ability of HSCs to self-renew has been
examined in multiple serial transplantation experiments by
measuring the lifetime of HSC clones derived from whole bone
marrow between 4 months and 2 years post-transplantation (Muller-
Sieburg et al., 2002). The conclusion was that self-renewal did not
contribute to the heterogeneity of the adult HSC compartment, and
that HSCs may have an intrinsic pre-determinate fate. Self-renewal
capacity was also quantified in single sorted (CD34− Lin− cKit+
Sca1+) HSCs by competitive repopulation assays in both primary
and secondary recipients, and the results showed that great diversity
exists in the repopulating activity between HSC clones (Ema et al.,
2005). Although all myeloid and lymphoid (B and T cell) lineages
were reconstituted from single HSC clones, the level of
reconstitution in each of the lineages was different.
As well as the ability to self-renew, the intrinsic cell cycle activity
of individual HSCs may contribute to HSC heterogeneity. The
results of two label-retention studies in mice – BrdU labelling or
histone marking with H2B-GFP synthesized during the active cell
cycle upon recombination in SCL-tTA transgenic mice – show that
most HSCs are dormant, label-retaining cells (Wilson et al., 2008).
Dormant HSCs can reversibly become active upon stimulation with
granulocyte colony stimulating factor (G-CSF; also known as Csf3)
or in response to bone marrow injury. BrdU label-retaining cell data
were further incorporated in computational models to enable an
estimation of the dormant and the active CD34− Lin− cKit+ Sca1+
CD150+ CD48− HSC turnover rates (van der Wath et al., 2009;
Wilson et al., 2009). The active HSCs are responsible for the
regular, everyday maintenance of the hematopoietic system, while
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the dormant HSCs divide rarely but can be activated upon injury.
The analysis predicted that dormant HSCs cycle once every 149-
193 days, whereas active HSCs cycle once every 28-36 days (van
der Wath et al., 2009; Wilson et al., 2009).
Multilineage hematopoietic outputs characterise HSC
subtypes in the bone marrow
The primary function of an HSC when transplanted into an
irradiated/myelodefective adult mouse recipient is the production of
mature hematopoietic cells that include cells of the myeloid
(granulocyte, macrophage), erythroid, platelet/megakaryocyte and
lymphoid (B and T cell) lineages. Measurement of mature
hematopoietic cell lineage outputs in the peripheral blood at 4-
6 months following clonal stem cell transplantation revealed that
HSCs fall into several subtypes. These could be retrospectively
classified as being ʻmyeloid-biased’ (also called ʻlymphoid-
deficient’), ʻlymphoid-biased’ (also called ʻmyeloid-deficient’)
and ʻmyeloid-lymphoid balanced’, based on the measurement of
the predominant lineages within the total output of donor-derived
HSCs (Cho et al., 2008; Muller-Sieburg et al., 2012) or based on the
relative contribution of each donor-derived lineage to the total
myeloid plus lymphoid cell population (both donor-derived and
recipient) (Dykstra et al., 2007) (Fig. 2). The HSC subtype with a
myeloid-lymphoid balanced output predominates in young adult
bone marrow from C57BL/6 mice (Dykstra et al., 2007). However,
the distribution of the HSC subtypes changed between young and
old (>38 week) mice, with an increase in the representation of the
myeloid-biased HSC subtype in older mice (Cho et al., 2008;
Dykstra et al., 2007). Secondary and tertiary transplantations
showed that the balanced and myeloid-biased HSCs are stable
subtypes, yielding the same lineage outputs in their daughter HSCs
over long periods of time (Benz et al., 2012; Cho et al., 2008;
Dykstra et al., 2007; Muller-Sieburg et al., 2002).
Recently, other HSC subtypes have been described. ʻPlatelet-
biased’ and ʻplatelet-myeloid-biased’HSCs were identified through
the transplantation of bone marrow-derived HSCs either expressing
or not expressing von Willebrand factor (vWF) (Sanjuan-Pla et al.,
2013). Platelet-biased and platelet-myeloid-biased HSCs were
enriched in the vWF+ subset, and vWF+ HSCs showed higher
myeloid and lower lymphoid contributions compared with vWF−
HSCs (Fig. 2).
Others have classified HSC subtypes into long-, intermediate-
and short-term (LT, IT and ST) repopulating HSCs based on the
reconstitution kinetics over a period of 24 weeks following clonal
HSC transplantation into primary recipients and 20 weeks in
secondary recipients (Yamamoto et al., 2013). Although all HSCs
were multilineage repopulating, the degrees of donor chimerism in
the myeloid lineage compared with the lymphoid lineage varied.
LT-HSCs exhibited high donor chimerism in all five lineages tested
– neutrophil/monocyte, erythrocyte, platelet, B cell and T cell – that
reached a threshold at 4 weeks post-transplantation and maintained
this threshold at 24 weeks in the primary recipient and also after
secondary transplantation. IT-HSCs displayed lower levels of
chimerism over the same period but began to lose myeloid and
erythroid output upon secondary transplantation. The ST-HSCs do
not provide a persistent level of chimerism in any of the five lineages
in the primary recipient over the 24-week period, and secondary
transplantations showed a predominantly lymphoid output.
The relationship between the LT/IT/ST classification system and
the other HSC subtype classifications (Cho et al., 2008; Dykstra
et al., 2007; Yamamoto et al., 2013) was assessed in a recent review
(Ema et al., 2014). Comparisons of the data showed that most of the
LT-HSCs in bone marrow were myeloid-biased, the majority of the
ST-HSCs were lymphoid-biased, and that the IT-HSC subtype
contained a mixed (balanced and lineage-biased) population of
HSCs. Since active HSCs enter the cell cycle every month and the
dormant HSCs every 5 months (Wilson et al., 2008), it would be
interesting to know whether the HSC subtypes based on cell cycle
and self-renewal activity overlap with the HSC subtypes based on
lineage output and long-term persistence in serial transplantations.
Molecular properties associated with bone marrow-derived
HSC subtypes
Evidence from a growing number of studies suggests that the
characteristic properties of HSC subtypes are primed intrinsically.
However, it has been difficult to obtain a molecular signature of the
different HSC subtypes associated with these properties because of
their inability to be prospectively isolated. HSCs are typically
purified from the adult bone marrow based on a combination of
markers, such as being Lin− Sca1+ cKit+ CD150+ CD48− (Kiel
et al., 2005). Refinements in this isolation procedure revealed that
the levels of CD150 (Slamf1), cKit and Sca1 (Ly6a) expressed on
the surface of HSCs differ, and that these differences are associated
with HSC functional heterogeneity when tested in repopulation
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Fig. 1. Possible ways in which hematopoietic stem cell (HSC)
heterogeneity may arise. (A) HSC types may originate from distinct
mesodermal cells that are prespecified early during development, distinct
endothelial cells or from the maturation of pre-HSCs in the dorsal aorta.
Hematopoietic cells are in pink, endothelial cells in blue and mesenchymal
cells in yellow. (B) HSC types may be regulated by distinct inductive
developmental tissues (for example the AGM, placenta, yolk sac, head) and
may change as they migrate through the circulation; or by developmental
niches, which may be vascular, hepatic, neural or bone; or by distinct
developmental mechanisms (e.g. EHT). (C) HSC types may have direct
lineage relationships whereby, after generation in the embryo, HSCs may
upregulate or downregulate receptors allowing differential priming and
responsiveness to specific signals that regulate lineage differentiation output,
quiescence and/or other stem cell characteristics. (D) HSC types may be
located in distinct adult bone marrow niches (for example osteoblastic,
perivascular, sinusoidal or spleen) that may change qualitatively or
quantitatively during development, aging and leukemia. It has yet to be
determined which of these models is responsible for the generation of HSC
heterogeneity, or indeed whether multiple models might work together. In
addition, epigenetic modifications might also explain the presence of distinct
HSC types. Understanding the origin of HSC heterogeneity will require further
experimentation to identify unique markers of HSC subtypes, to better
characterise different HSC niches and the localisation of HSC subtypes within
them, and to precisely lineage trace HSC subtype generation throughout
development.
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assays (Kent et al., 2009; van der Wath et al., 2009; Wilson et al.,
2009; Morita et al., 2010). Indeed, compared with the CD150medium
and CD150low HSCs, CD150high HSCs show greater self-renewal
capacity in serial transplantation assays. Moreover, flow cytometric
index sorting combined with single-cell RNAseq and single-cell
transplantation verify that, based on the CD150 and Sca1 expression
levels, HSCs differ in the kinetics of cell division and
differentiation. CD150+ Sca1low cells were significantly more
proliferative than CD150+ Sca1high cells, suggesting that the latter
are the dormant HSCs. In combination with index sorting data,
single-cell gene expression signatures suggest that dormant HSCs
have the ability to respond to stress and injury. Furthermore, overlay
between single-cell gene expression data and single-cell
transplantation results uncovered a difference between
repopulating and non-repopulating HSCs based on homing abilities.
cKit is another molecular marker that has been used to distinguish
between HSCs with different repopulation characteristics following
transplantation. Purified HSCs that express intermediate levels
(cKitint), which are normally quiescent in situ in the steady-state
bone marrow, are highly proliferative after transplantation and can
efficiently repopulate secondary and tertiary recipients. By contrast,
cKithigh HSCs have low expansion capacity and reduced repopulating
activity in primary recipients and after serial transplantations
(Grinenko et al., 2014). These findings were supported by cell cycle
analysis, which showed that cKitint HSCs are quiescent comparedwith
the cycling cKithigh HSCs. Transcriptomic analyses show molecular
differences between these two HSC subtypes: genes related to cell
adhesion and VEGFR signalling were upregulated in cKitint HSCs
compared with cKithigh HSCs, whereas cell cycle genes were
downregulated in cKitint HSCs compared with cKithigh HSCs. The
existence of two HSC subtypes based on cKit expression was also
demonstrated by Shin et al. (2014). In this study, purified cKitlowHSCs
exhibited long-term reconstitution potential and enhanced self-renewal
capacity when transplanted into primary and secondary recipients, in
contrast to cKithigh transplanted HSCs. Both subpopulations
reconstitute irradiated recipients; however, the ability of the cKithigh
population to self-renew was lost 4 weeks after the secondary
recipients were transplanted (Grinenko et al., 2014). Together, these
two studies demonstrate both in vivo and in vitro that different HSC
subtypesmarked by varying levels of cKit are hierarchicallyorganised,
and that an increasing level of cKit expression corresponds with the
start of differentiation. Thus, distinct levels of cKit expression are
associated with specific functional repopulation and self-renewal
characteristics of HSC subtypes.
HSCs that express different levels of CD150 and cKit have also
been examined for their association with hematopoietic lineage
output following transplantation (Fig. 2). In one study it was shown
that differing levels of CD150 expression distinguish HSCs with
different lineage outputs (Beerman et al., 2010). Upon
transplantation of 10 or 180 sorted HSCs per recipient mouse in
competitive repopulation assays, CD150high HSCs gave a
predominant myeloid-biased output, whereas CD150low gave a
lymphoid-biased lineage output. Interestingly, when two HSC
populations defined by the cKit surface expression level were
examined by FACS for CD150 expression, no differences in the
level of CD150 were found. Moreover, cKithigh and cKitint HSCs
showed comparable lineage outputs as measured in the peripheral
blood of primary recipients upon transplantation in limiting dilution
experiments (Shin et al., 2014). In the same study, however, in vitro
assays demonstrated that cKithigh HSCs exhibit a megakaryocytic
differentiation bias.
Hoechst dye efflux is another method of HSC isolation and
produces a population termed the side population (SP) (Goodell
et al., 1996). Different SP subfractions correlate with HSC subtypes.
For example, the lineage output of clonally transplanted Lin− Sca1+
cKit+ bone marrow cells from the lower SP region was enriched in
myeloid-biased HSCs, whereas that from the upper SP region was
enriched in lymphoid-biased HSCs (Challen et al., 2010). In
addition, the CD229 (Ly9) marker was used to further isolate HSCs
within the Lin− Sca1+ cKit+ CD150+ CD48− CD244− bone marrow
fraction. CD229− cells contained 79% myeloid-biased HSCs, 7%
balanced and 14% lymphoid-biased HSCs. CD229+ cells contained
22% myeloid-biased, 22% balanced and 56% lymphoid-biased
HSCs (Oguro et al., 2013). Hence, high-purity sorting of HSCs
based on cell surface markers as well as SP regions indicate a
correlation between molecular phenotype and lineage output.
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Fig. 2. The relationship between bone marrow HSC lineage output, phenotype and responsiveness to signalling pathways. CD229, CD150, vWF and
Hoechst dye efflux (SP) were used together with canonical HSC markers (Lin− Sca1+ cKit+ or Lin− Sca1+ cKit+ CD48− CD150+) to enrich myeloid-biased,
lymphoid-biased or platelet-biased HSCs (*here, platelet-biased HSCs also include platelet-myeloid-biased HSCs). In addition to the canonical HSC markers
used, HSC fractions sorted by Yamamoto et al. (2013) wereCD34−. Myeloid-biasedHSCs are generally activated by the TGFβ signalling pathway (blue), whereas
lymphoid-biased HSCs are inhibited (white). All myeloid-lymphoid (balanced) HSCs are BMP-activated (red). The myeloid-biased HSCs are mostly non-BMP-
activated (white). The lymphoid-biased HSCs are equally distributed between BMP-activated and non-BMP-activated fractions.
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It was previously suggested that adult bone marrow myeloid-
biased or lymphoid-biased HSC subtypes could be distinguished by
their responsiveness to factors released by their surrounding
microenvironment. For example, the loss of responsiveness of the
myeloid-biased HSCs to interleukin 7 (IL7) may be due to the
downregulation of IL7 receptor (IL7R) (Muller-Sieburg et al.,
2004). Lymphocytes derived from myeloid-biased HSCs showed
downregulation of IL7Rα gene and protein expression as compared
with those derived from lymphoid-myeloid balanced HSCs. Indeed,
another study reported that lymphoid-myeloid balanced HSCs show
significantly higher expression of lymphoid gene regulators, such as
Pax5, Il7r, E2a (Tcf3) and Ikaros (Ikzf1), than myeloid-biased
HSCs (Benz et al., 2012).
Interestingly, myeloid-biased and lymphoid-biased HSCs are
differentially responsive to the TGFβ signalling pathway upon
exposure in vitro or injection of TGFβ1 into mice in vivo (Fig. 2). In
all cases, TGFβ promotes proliferation and myeloid differentiation
in a dose-dependent manner, specifically in myeloid-biased HSCs
(Challen et al., 2010). It induces opposing transcriptional responses
in the two HSC fractions for genes related to cell cycle activation,
lymphoid versus myeloid differentiation genes and even oncogenes.
Recently, activation of BMP signalling in the bone marrow was
found to be associated with balanced and lymphoid-biased HSCs,
whereas more myeloid-biased HSCs were found in the non-BMP-
activated fraction (Crisan et al., 2015) (Fig. 2). Transcriptomic data
from these sorted HSC fractions showed that gene targets of
decitabine, a small molecule hypomethylating agent that inhibits
DNA methyltransferase (Kantarjian et al., 2006), were significantly
upregulated in BMP-activated HSCs and significantly
downregulated in non-BMP-activated HSCs. Decitabine is used
today to treat patients with myelodysplastic syndrome and acute
myeloid leukemia (Kantarjian et al., 2003).
Altogether, these studies have yielded insight into the some of the
intrinsic molecular differences between HSC subtypes.
Exploring the possible origins of HSC heterogeneity
Given the relationship between HSC lineage output, molecular
phenotype and responsiveness to signalling pathways, it is of great
interest to understand the origins of HSC heterogeneity. There are
several different scenarios that might explain how HSC
heterogeneity arises, including the influence of distinct HSC
niches in the adult bone marrow, a direct lineage progression from
one HSC type to another, distinct embryonic origins, and/or
different developmental microenvironments (Fig. 1). For the
remainder of this Review, we discuss each of these scenarios and
evaluate the evidence both for and against each one.
The bone marrow microenvironment and HSC heterogeneity
Adult HSC function may be related to HSC localisation within the
bone marrow niches. Recent studies focusing on the mouse bone
marrow niche have demonstrated that the HSC-supportive niches
are composed of combinations of highly diverse ‘stromal’ cell
types. Cells that comprise these niches include osteoblasts,
macrophages, megakaryocytes, sympathetic nervous system
cells, endothelial cells, and perivascular and perisinusoidal
mesenchymal stromal/stem cells (Boulais and Frenette, 2015).
This implies that distinct stromal cell factor combinations and/or
distinct cell contacts between different types of stromal cells and
HSCs can control HSC quiescence, survival, proliferation, self-
renewal and mobilisation/or retention in their niche (Wohrer et al.,
2014), and hence could form the basis of what is described as
HSC heterogeneity.
Some bone marrow HSCs are in direct contact with osteoblasts.
Conditional ablation of osteoblasts results in bone loss and
significantly decreases the number of HSCs as well as myeloid,
erythroid and lymphoid progenitors (Visnjic et al., 2004). This is in
line with a converse study that showed an increase in the number of
HSCs concomitant with an increased number of osteoblasts as a
result of the osteoblast-specific conditional inactivation of Bmpr1a
(Zhang et al., 2003). These results demonstrate that HSC numbers
are dependent on niche size, which is mediated by the BMP
signalling pathway. However, bone marrow HSCs are also found in
contact with macrophages, megakaryocytes, endothelial cells and
perivascular cells. Bone marrow macrophages release CXCL12
(SDF1), which is a potent chemoattractor of HSCs, and osteocalcin
(Bglap), and both act to support osteoblast survival, thereby
retaining HSCs in their niche (Chow et al., 2011; Christopher et al.,
2011). Deletion of CD169 (Siglec1)+ macrophages leads to
decreased retention of HSCs in the mesenchymal niche in the
bone marrow and consequently HSCs are mobilised in the blood
stream (Chow et al., 2011). In line with this study, G-CSFR (Csf3r)
has been reported to signal in monocytes to mobilise HSCs in the
blood stream by suppressing the supportive role of osteoblasts and
disrupting the CXCR4/CXCL12 axis (Christopher et al., 2011).
Owing to the intimate cross-talk between osteoblasts and
macrophages in their regulation of HSC maintenance, it is
difficult to dissociate these cell types as being distinct HSC-
supportive niches. In contrast to macrophages, the sympathetic
nervous system facilitates HSC mobilisation and migration (Chow
et al., 2011; Katayama et al., 2006).
HSCs are also found in direct contact with megakaryocytes,
which are cells at the crossroads of regulating HSC quiescence and
expansion. Megakaryocytes normally secrete cell cycle regulators
such as thrombopoietin, TGFβ1 and CXCL4, which keep HSCs in
G0 of the cell cycle (Nakamura-Ishizu et al., 2014; Bruns et al.,
2014; Zhao et al., 2014). However, under the chemotherapeutic
stress of the small molecule 5-flurouracil, megakaryocytes secrete
FGF1 and downregulate TGFβ1, stimulating the expansion of HSCs
(Zhao et al., 2014).
Endothelial cells are essential for the self-renewal and
repopulation activity of HSCs through release of angiocrine
factors that activate the Notch or Akt signalling pathways (Butler
et al., 2010; Kobayashi et al., 2010; Poulos et al., 2013). Recent
work demonstrated that more than 94% of HoxB5-marked HSCs in
the bone marrow are found in an ablumenal position, directly
attached to VE-cadherin (Cdh5)-expressing endothelial cells (Chen
et al., 2016). These HoxB5-marked HSCs represent between 7%
and 35% of phenotypic HSCs when classic markers are used – for
instance Lin− Sca1+ cKit+ CD150+ CD48− – suggesting that this
compartment remains heterogeneous.
Other recent studies have shown that bone marrow HSCs are in
contact with perivascular mesenchymal cells, which regulate HSC
cell cycle activity by secreting stem cell factor (SCF; also known as
Kitl) and CXCL12 (Ding and Morrison, 2013; Ding et al., 2012;
Omatsu et al., 2010). Conditional deletion of Scf in endothelial cells
and Leptin receptor-expressing perivascular cells results in
decreased bone marrow HSC numbers (Ding et al., 2012).
Deletion of Scf from hematopoietic cells, osteoblasts and nestin-
expressing cells did not affect HSC number or function. When
CXCL12-abundant reticular (CAR) perivascular cells were
depleted, HSCs were also reduced in number and were more
quiescent, suggesting a key role for these cells and the chemokine
that they secrete in controlling HSC proliferation (Omatsu et al.,
2010). Whether CXCL12-expressing perivascular cells are mainly
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found in the arteriolar wall or around sinusoids remains unclear. It
was shown that arteriolar perivascular cells expressing NG2
(Cspg4) maintain HSC quiescence (Kunisaki et al., 2013).
However, deep imaging of bone marrow shows that the non-
dividing HSCs are mainly associated with sinusoidal perivascular
Leptin receptor-expressing cells (Acar et al., 2015). HSC cell cycle
regulation is thus based on their proximity to one or other stromal
cell type, which cooperate with endothelial cells to support HSCs
(Greenbaum et al., 2013).
Finally, HSC localisation in the bone marrow niche can be
modulated intrinsically by nuclear factor-like 2 (Nrf2; also known
as Nfe2l2), a master regulator of the oxidative stress response. This
factor, expressed by HSCs themselves, acts as a negative regulator
of cell cycle progression by partially regulating CXCR4 expression
(Tsai et al., 2013).
On their own, local blood perfusion and hypoxia can functionally
separate HSC populations in the bone marrow niche (Lévesque and
Winkler, 2011).
Altogether, these observations suggest that HSC heterogeneity is
supported by the high diversity of cell types found in the supportive
niches of the bone marrow; however, it remains unknown whether
HSC heterogeneity is unique to the bone marrow or whether some
HSC subtypes are developmentally determined.
The developmental counterparts of adult HSC subtypes
During development of the adult hematopoietic system, HSCs are
localised in several different microenvironments that are not only
supportive but also elicit unique inductive and expansion properties
(Dzierzak and Speck, 2008) (Fig. 3). Initially, within the inductive
microenvironment of the embryo, HSCs arise from specialised
endothelial cells in the aorta and other major vasculature (de Bruijn
et al., 2002, 2000) that undergo transdifferentiation to an HSC fate.
HSCs can also be detected in the yolk sac (Kumaravelu et al., 2002),
placenta (Gekas et al., 2005; Ottersbach and Dzierzak, 2005) and
head of the embryo (Dzierzak and Speck, 2008; Li et al., 2012). As
shown in the mouse model, these HSCs are robust, self-renewing
and can achieve high-level, long-term multilineage engraftment into
adult irradiated recipients following clonal transplantation (Taoudi
et al., 2008). Following their generation and short-termmaintenance
in the vascular regions of the embryo, HSCs migrate and colonise
the fetal liver, where they expand and are maintained until shortly
before birth, at which point they again migrate and finally reside in
the bone marrow in HSC-supportive niches (Dzierzak and Speck,
2008) (Fig. 3). Thus, HSCs experience several distinct
microenvironments during development, and accumulating
evidence suggests that HSC heterogeneity begins at these early
developmental stages.
HSCs of the embryo, fetal liver, neonatal bone marrow and adult
bone marrow have been studied and compared for properties such
cell cycle, self-renewal and lineage output. Almost 100% of HSCs
in the E14.5 fetal liver were found to be actively cycling, compared
with only ∼10% of adult bone marrow HSCs – indeed, most adult
bone marrow HSCs are quiescent (Fleming et al., 1993; Morrison
et al., 1995; Bowie et al., 2006). Little is known regarding the cell
cycle status of HSCs during the inductive phase in the embryo, since
the paucity of aortic HSCs precludes precise measurements. Only
very rare hematopoietic cells expressing the proliferation marker
Ki67 are detected on E11.5 aorta-gonad-mesonephros (AGM)
frozen sections (Mirshekar-Syahkal et al., 2013). The E10 mouse
aortic region was also examined in thick slices stained for CD31
(Pecam1), cKit and phospho-histone H3.3 (PHH3), and showed a
low mitotic index for the hematopoietic cluster cells (Boisset et al.,
2015). Differences have also been found in the self-renewal
properties of HSCs over the developmental timecourse. Fetal liver
and umbilical cord HSCs appear to have more proliferative potential
and can be serially transplanted more times that adult bone marrow
HSCs (Bowie et al., 2007; Harrison et al., 1997), suggesting that
developmentally young (fetal and neonatal) HSCs are more
robustly self-renewing. The higher proliferation ratio in the fetal
liver compared with the adult bone marrow was also observed more
recently, and the authors suggested that it was driven by a higher
mitochondrial content and activity, coupled with elevated oxygen
consumption, in the HSCs purified from fetal liver (Manesia et al.,
2015). However, the existence and possible influence of distinct
niches – and the distinct cellular types within them – cannot be ruled
out. For example, only ∼45% of HSCs were lost in E14.5 fetal liver
in which perivascular (NG2-expressing) cells were deleted as
compared with control wild-type fetal liver cells (Khan et al., 2016),
suggesting that other external stimuli or cells control HSC
expansion and/or maintenance. It would be interesting to
investigate whether a certain HSC subtype is associated with
portal vessels containing NG2-expressing perivascular cells.
As early as the fetal liver stage, HSC subtypes can be found that
show heterogeneity in their lineage output. Clonal transplantations
of mouse fetal liver HSCs show HSC subtypes similar to those
found in the adult bone marrow: lymphoid-deficient balanced and
myeloid-deficient were found at E14.5 (Benz et al., 2012).
Interestingly, the proportions of these HSC subtypes are reversed
in the fetal liver as compared with their adult bone marrow
counterparts. Whereas with aging, the adult bone marrow contains
proportionally more myeloid-biased (or lymphoid-deficient) HSCs
(Benz et al., 2012; Cho et al., 2008), the E14 fetal liver contains 10-
fold more myeloid-lymphoid balanced than myeloid-biased HSCs
(Benz et al., 2012). The proportional representation of HSC
subtypes might be dependent to some degree on the different
microenvironments of the fetal and/or adult stages as a consequence
of different extrinsic locally released microenvironmental factors.
For example, the bone marrow niche might produce more factors
that maintain myeloid-biased HSCs, whereas the fetal liver might be
rich in factors that expand/maintain myeloid-lymphoid (balanced)
HSCs.
Molecular changes during HSC emergence: fetal liver compared with
bone marrow
The intrinsic gene regulatory programmes that dictate the
bifurcation of HSCs into subtypes is of interest, since this may
affect reprogramming strategies to direct non-hematopoietic cells to
HSC fate. Molecular studies of HSCs isolated from different
developmental stages have highlighted some genes that may play a
role in HSC subtype appearance and/or behaviour. In two separate
studies, gene expression profiles of fetal liver-derived versus adult
bone marrow-derived HSCs revealed that the Sox17 transcription
factor is specifically expressed in fetal and neonatal (up to 4 weeks)
HSCs, but not in adult HSCs (He et al., 2011; Kim et al., 2007).
Sox17 is expressed in the hemogenic endothelium, emerging HSCs
and also in the intra-aortic cell clusters (Clarke et al., 2013;
Nobuhisa et al., 2014). Germline deletion of Sox17 causes severe
fetal hematopoietic defects and an absence of definitive HSCs.
Conditional deletion of Sox17 during mid-gestation using
endothelial-directed Cre [driven by Tie2 (Tek) or VE-cadherin]
resulted in lethality at E13.5. When Sox17 was deleted in
hematopoietic cells in 2- to 6-day-old neonates using Mx1-Cre, all
mice died by 14 days after birth. However, conditional deletion of
Sox17 in hematopoietic cells of 6-week-old mice usingMx1-Cre did
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not affect hematopoiesis. These data suggest that Sox17 is required
for the maintenance of neonatal but not adult HSCs, and that Sox17
is a key determinant of the earliest stages of HSC identity.
Additional members of the SOX family, Sox7 and Sox18, are also
expressed in the dorsal aorta of the mouse embryo and show similar
effects in the formation of cell clusters with hematopoietic activity
(Nobuhisa et al., 2014). Both Sox17 and Sox18 are significantly
upregulated in hemogenic endothelial cells compared with
endothelial cells isolated from the AGM at the time of the
endothelial to hemogenic transition (Solaimani Kartalaei et al.,
2015). Sox7 and Sox17 are not only required at this stage but also
much earlier, between E7 and E8.5, as shown by single-cell gene
expression measurements (Moignard et al., 2015). In that study, the
authors showed that downregulation of Sox7 is key during erythroid
development from the early mesoderm.
In addition to the stage-specific requirement for members of the
SOX family, another hematopoietic transcription factor, C/EBPα,
has also been implicated in the specification of developmental
versus adult HSC types. Loss of Cebpa inMx1-Cre adult transgenic
mice confers a gain of fetal HSC-type characteristics on the bone
marrow HSCs, including proliferation ratio and number of
repopulating HSCs (Ye et al., 2013). Other factors, such as
polycomb repressive complex 2 (PRC2), Bmi1 and Etv6 (Tel),
function in adult HSCs but not in fetal liver HSCs (Xie et al., 2014;
Copley et al., 2012). By contrast, Prom1 was shown to be expressed
by hemogenic precursor cells in the mid-gestation placenta (Pereira
et al., 2016). Cells with a similar phenotypewere also detected in the
mid-gestation AGM but not among E13.5 fetal liver or adult bone
marrow HSCs. This group further purified and analysed the Prom1+
hemogenic cells by mRNA sequencing, confirming both
endothelial and (low-level) hematopoietic gene expression
(Pereira et al., 2016). Other genes, such as Fgd5 and Ctnnal1
(also known as α-catulin), are expressed throughout HSC ontogeny.
Fgd5 is predominantly expressed in HSCs in both adult bone
marrow and embryonic hematopoietic sites (Gazit et al., 2014).
Although lethal at E12, Fgd5 deficiency did not affect the
generation and function of HSCs in vivo, suggesting a
requirement for this factor outside of hematopoietic development.
Ctnnal1 was detected in both adult bone marrow HSCs and
precursors of HSCs in the AGM (Acar et al., 2015; Zhou et al.,
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Fig. 3. Distribution of HSCs and heterogeneity in developmental niches. HSC development is time and tissue dependent. HSCs are located in multiple
intraembryonic tissues, including the aorta, vitelline and umbilical arteries (V/U), head and liver, and the extraembryonic tissues, yolk sac (YS) and placenta (PL).
At the fetal stage, the liver provides niches for HSC expansion and maintenance. In the adult, HSCs are found in a variety of niches in the bone marrow. HSC
heterogeneity is summarised beneath in terms of types (top) and subtypes (middle), with associated references. Only percentages comparing fetal liver and bone
marrow are shown. nt, not tested; Ly, lymphoid-biased; My, myeloid-biased. Bone marrow values refer to 3-6, 2-3 or 8-10 months (m) old.
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2016) and it too is not required for HSC development. Only 30% of
the AGM pre-HSC gene signatures were shared by adult bone
marrow HSCs (Zhou et al., 2016), suggesting that heterogeneity can
be tissue- and developmentally derived. The fact that there are
intrinsic molecular differences between HSCs at embryonic, fetal
and adult stages, and that HSC heterogeneity already exists at the
fetal liver stage of development raises questions as to when HSC
subtypes first appear in development and how this might occur.
The emergence of HSC subtype specification
Heterogeneity of HSCs may begin as early as the time when HSCs
are first being generated, and involve a variety of inductive
mechanisms and different microenvironments. In the mouse
embryo, the first LT-HSCs are detected and generated at E10.5 in
the AGM region. LT-HSCs are also found in other parts of the
embryo, namely the yolk sac, vitelline/umbilical arteries, placenta
and head. It might be that the generation of HSCs in these different
sites at slightly different developmental stages is the source of – or at
least a contributory factor to – the HSC lineage output heterogeneity
found in the fetal liver. For example, embryonic head HSCs express
Sca1GFP, a marker of all AGM HSCs (de Bruijn et al., 2002), and
although Sca1GFP+ AGM cells undergo endothelial-to-
hematopoietic transition (EHT) (Boisset et al., 2010), there is no
evidence to suggest that EHT occurs in the embryonic head (Iizuka
et al., 2016; Li et al., 2016). Thus, different mechanisms for HSC
generation may exist. These, together with the diverse and dynamic
developmental microenvironments might induce the generation of
different HSC subtypes. Interestingly, a recent study showed that
cultured mesenchymal stromal cell lines derived from different
anatomical sites express distinct transcriptional programmes
(Charbord et al., 2014). Since, in situ, the mesenchymal stromal
cells form part of the HSC niche, it might be that their different
transcriptional programmes reflect different molecular requirements
for the maintenance of distinct HSC subtypes.
Hemogenic endothelial cells have been shown to be the direct
precursors to HSCs, taking on a hematopoietic fate during a limited
window of developmental time (Boisset et al., 2010; Chen et al.,
2009; Zovein et al., 2008). Could these cells be the ultimate source
of HSC heterogeneity? Hemogenic endothelial fate may be
separated from cells with strictly endothelial fate at early stages,
and is likely to be derived from the partitioning of mesodermal
populations; for example, extraembryonic versus lateral versus axial
fate. Differences in the hemogenic potential of ventral-lateral versus
other mesoderm has been shown in chick embryonic aorta
(Pardanaud et al., 1996). Human pluripotent stem cell
hematopoietic differentiation cultures also show that hemogenic
endothelium and vascular (arterial and venous) endothelium
represent separate lineages (Ditadi et al., 2015). In mouse
embryos, hemogenic endothelial cells are detected at least 2 days
before HSCs are generated (Swiers et al., 2013), and there is
evidence suggesting that presumptive aortic hemogenic endothelial
cells are found in the lateral mesoderm of E7.5-E8.5 mouse embryos
and require the transcription factors Etv2 and Hoxb6 (Kataoka et al.,
2013). This hemogenic competence of endothelial progenitors was
further shown to be restricted by Runx1 silencing (Eliades et al.,
2016). Interestingly, a subset of endothelial cells and hematopoietic
cells located ventrally in the E10.5 AGM and a subset of endothelial
cells and hematopoietic progenitor/stem cells in the E15.5 fetal liver
can be derived from PDGFRα+ early paraxial mesodermal cells, as
shown by cell tracing in which PDGFRα+ cells were labelled at
E7.5-E8 by tamoxifen injections into pregnant females (Ding et al.,
2013). However, PDGFRα is dispensable for the development of
fetal liver hematopoiesis and Pdgfra-deleted mice die from a
cephalic closure defect and skeletal abnormalities (Soriano, 1997).
In addition, rare endothelial cells in the blood vessels of the head
and cardiomyocytes were also marked. These results highlight the
possibility that HSC subtypes might be determined at much earlier
developmental stages than previously thought, and in different
mesodermal populations.
Another possible source of HSC heterogeneity is the
hematopoietic cells generated prior to the generation of LT-HSCs.
In a neonatal transplantation scenario, the cKit+ CD34+ cell fraction
of E9 yolk sac was shown to contribute to long-term chimerism,
suggesting the existence of pre-HSCs (Yoder et al., 1997). Indeed,
reaggregate cultures of AGM cells defined as pre-HSCs by
phenotype and function were able to exhibit LT-HSC activity
when transplanted into irradiated adult recipients (Taoudi et al.,
2008). More recently, myeloid-lymphoid hematopoietic progenitors
(also called immature HSCs or imHSCs) derived in the yolk sac and
harboured in the E9.5 fetal liver were shown to contribute to
definitive hematopoiesis when injected into irradiated adult
recipients, albeit with low chimerism. Upon organ culture of E10
fetal liver in the presence of thrombopoietin, these cells were able to
reconstitute the hematopoietic system of natural killer-competent
mice (Kieusseian et al., 2012). More recent studies have shown that
the number of pre-HSCs increases dramatically in the AGM from
E9 and peaks at E11.5 (Rybtsov et al., 2016). This was further
confirmed by single-cell RNAseq analysis showing that a subset of
pre-HSCs in the AGM is enriched in cell division-related genes such
as Hmmr (Cd168) (Zhou et al., 2016). The rapid decrease in pre-
HSCs in the E11.5 AGM and abrupt, but similar, increase in the
number of definitive HSCs in the fetal liver led the authors to
suggest that subsets of definitive HSCs in the fetal liver originate
from the maturation of AGM-derived pre-HSCs upon migration into
their new microenvironment (Rybtsov et al., 2016).
Despite these interesting findings, there is still no direct in vivo
evidence to demonstrate that distinct pre-HSCs or imHSCs
contribute to HSC types found at later stages. Nonetheless, the
asynchronous and graded cellular maturation could explain the
heterogeneity of HSCs in the fetal liver. Individual cells might
require different microenvironments to mature or may mature at
different rates (Moignard et al., 2015). Based on these studies, it is
now important to understand whether the pre-HSCs in the AGM, the
imHSCs in the fetal liver and/or the HSCs in the yolk sac, placenta
and head show distinct lineage outputs.
Is more than one type of HSC generated in the AGM region?
HSC generation in the AGM region occurs in a polarised manner,
with HSCs detected only on the ventral side of the aorta (Medvinsky
et al., 2011; Taoudi et al., 2008). The initiation of HSC generation is
tightly controlled by the local microenvironment: the ventral aortic
endothelium and/or subaortic mesenchyme express molecules that
trigger EHT and subsequent generation of HSCs (Richard et al.,
2013; Durand et al., 2007; Pouget et al., 2014; Kaimakis et al., 2013;
Robin and Durand, 2010). Of these molecules, BMP is expressed in
the ventral aspect of the AGM in mesenchymal and aortic
endothelial cells (Durand et al., 2007; Marshall et al., 2000) and
has been shown to affect HSC activity in AGM explant cultures
(Durand et al., 2007). The Runx1 and Gata2 transcription factors
also show expression in the ventral aspect of the aorta at E10.5 and
are required for hematopoietic progenitor and stem cell generation
from hemogenic endothelium (Chen et al., 2009; Tober et al., 2013).
Moreover, Notch signalling is essential for EHT in vivo (Gama-
Norton et al., 2015), initiating endothelial cell fate change to a
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hematopoietic cell in the AGM through the Notch ligand jagged 1
(Robert-Moreno et al., 2008; Gerhardt et al., 2014; Guiu et al.,
2014; Tang et al., 2013). Notch 1 is expressed in most of the cells of
the intra-aortic hematopoietic clusters, similar to jagged 1 (Robert-
Moreno et al., 2008). A signalling cascade linking some of the
factors has been shown in zebrafish embryos. Here, BMP and
Hedgehog act through VEGF/Notch signalling to polarise HSC
emergence from the dorsal aorta (Gering and Patient, 2005;
Wilkinson et al., 2009).
TwoHSC subtypes that differ in activation by the BMP signalling
pathway were identified in studies that examined HSC development
in the AGM in vivo and in vitro. Based on a BMP activation marker,
HSCs generated in the E11 AGM in vivo are of one type: BMP-
activated (Crisan et al., 2015). However, when AGM explants are
cultured prior to transplantation, two HSC subtypes are found:
BMP-activated and non-BMP-activated HSCs (Crisan et al., 2016).
Furthermore, it was found in AGM explant cultures that the non-
BMP-activated HSCs were affected by the Hedgehog signalling
pathway through VEGF, which is most likely produced by
endothelial cells. Serial transplantation experiments suggested that
whereas BMP-activated AGM HSCs yielded both BMP-activated
and non-BMP-activated HSCs, non-BMP-activated HSCs yield
only non-BMP-activated HSCs. This might indicate differences in
the niche between the AGM and bone marrow. It has yet to be
determined through lineage tracing whether the induction of all
HSCs requires activation of the BMP signalling pathway.
The two HSC types that differ in their responsiveness to BMP
were also found in vivo in the E12-E14 fetal liver. Limiting dilution
transplantations of E14 fetal liver show that 80-90% of fetal liver
HSCs are of the BMP-activated subtype (Crisan et al., 2015).
Interestingly, the canonical BMP signalling pathway has been
shown in Smad1/5 knockout experiments to be dispensable for fetal
liver HSC activity (Crisan et al., 2015; Singbrant et al., 2010),
suggesting that, in the absence of BMP-activated HSCs, normal
hematopoietic activity is maintained by the non-BMP-activated
HSCs. When lineage output was assayed by clonal transplantation
of fetal liver BMP-activated and non-BMP-activated HSCs, both
fractions were found to contain balanced and lineage-biased HSC
subtypes (Crisan et al., 2015). In contrast to the fetal liver, most
bone marrow HSCs are of the non-BMP-activated type (Crisan
et al., 2015). Clonal transplantations of bone marrow HSCs showed
that all myeloid-lymphoid balanced HSCs are BMP-activated,
whereas the majority of myeloid-biased HSCs are not activated by
the canonical BMP pathway (Fig. 2).
Adult bone marrow HSCs are also controlled by TGFβ signalling
(Yamazaki et al., 2009). Myeloid-biased and lymphoid-biased
HSCs can be distinguished based on their response to the TGFβ
signalling pathway, although not all HSC clones cleanly segregate
between the two subgroups (Challen et al., 2010). Myeloid-biased
HSCs are generally activated by TGFβ, whereas the lymphoid-
biased HSCs are inhibited.
These results highlight the developmental changes that occur in
HSCs and suggest that the bone marrow niche might influence HSC
subtypes via the specific developmental growth factors that they
secrete.
Summary and future perspectives
HSC heterogeneity exists in vivo from early developmental stages,
and different HSC subtypes can be detected as early as the fetal liver
stage. HSC subtypes exhibit measurable functional properties, such
as lineage output or self-renewal ability, and can be prospectively
enriched based on surface expression levels of CD150 and cKit, or
their responsiveness to the BMP or TGFβ developmental signalling
pathways. Although as yet unknown, it is likely that gradients of
these morphogens drive the emergence of different HSC types. The
responsiveness to these signalling pathways is in association with,
but not in complete correlation to, lineage output. Intrinsic
molecular differences in HSCs from the fetal liver and adult
stages have been found, and genes have been associated with
specific HSC lineage outputs. However, the molecular networks
that regulate the generation of specific HSC subtypes remain
unknown, as do the developmental cellular precursors of HSC
types. The changing balance and frequencies of HSC subtypes in
the embryonic, fetal and adult microenvironments support the
notion that distinct developmental niches are present and
differentially affect the persistence and representation of specific
HSC types and behaviours. Some studies are beginning to show that
the maintenance of self-renewal of the HSCs that colonise the fetal
liver depends on the interaction with the endothelial and
perivascular cells (Iwasaki et al., 2010; Khan et al., 2016;
Tamplin et al., 2015). Future studies should reveal the specific
developmental niche compartments and factors that regulate the
induction, maintenance, expansion and balance of HSC subtypes.
The physiological relevance of having different HSC types and
subtypes is as yet uncertain. It is possible that lineage-biased HSCs
in the bone marrow of the adult could confer an advantage during
stress conditions or trauma in which the rapid replacement of a
specific lineage of hematopoietic cells is required. In blood-
associated cancers, some leukemias are of the myeloid type,
whereas others are of the lymphoid type. Specific HSC subtypes in
the adult or in the fetal stages might therefore serve as the targets of
pre-leukemic events, and thus restrict the malignancy to the myeloid
or lymphoid lineage. Additionally, the balance between the types of
HSCs might change during hematological disease. Whether only
HSCs are being mobilised under these conditions is unclear. A
recent study proposed that steady-state hematopoiesis is derived
from long-lived progenitors, both restricted and multipotent, rather
than LT-HSCs (Sun et al., 2014). However, this model is not
supported by hematological data on HSCs, erythroid progenitors
and myeloid progenitors accumulated from aplastic anemia patients
(Notta et al., 2016). Clonal tracking of genetically modified HSCs
over 4 years following transplantation and hematopoietic
reconstitution revealed that it takes ∼6-12 months to reach a
normal and stable hematopoietic output. Importantly, this study
demonstrated that steady-state hematopoiesis after transplant is
maintained by both HSCs and multipotent progenitors (Biasco
et al., 2016). Thus, it is important to properly investigate whether
and how particular HSC subtypes contribute to specific hematologic
disease. Our further understanding of the molecular regulators of
specific HSC subtypes through transcriptome approaches should
provide important information that can be applied in patient-specific
treatments, particularly in leukemias to eradicate the affected HSC
type while preserving the healthy HSC types for hematopoietic
function.
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